Heidi Stout, Senior MRD Sales Specialist at Myriad Genetics, shared a post on LinkedIn:
“I’m excited to share that I’ve joined Myriad Genetics on Tara Zaloudek‘s team as we prepare to bring Molecular Residual Disease (MRD) testing to breast cancer. For years, Myriad Genetics has been a trusted leader in breast cancer diagnostics — helping clinicians assess hereditary risk and guide critical treatment decisions.
Now, building on that foundation, we’re advancing into molecular recurrence detection. I’ve seen firsthand how much uncertainty patients carry after curative-intent treatment. MRD has the potential to provide something we’ve been missing — greater clarity. For clinicians. And for the women they care for. Breast cancer care is deeply personal. It deserves tools that are equally precise and meaningful.
I’m looking forward to connecting with forward-thinking oncologists, breast specialists, and healthcare leaders shaping the future of recurrence monitoring. If you’re exploring how MRD may fit into your practice, I’d welcome the conversation. Grateful to be part of this launch covering the Great Lakes Territory.
Energized for what’s ahead.”